<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment and prevention of &lt;i&gt;Legionella&lt;/i&gt; infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment and prevention of
       <i>
        Legionella
       </i>
       infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment and prevention of
        <i>
         Legionella
        </i>
        infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Murdoch, MD, MSc, DTM&amp;H, FRACP, FRCPA, FFSc(RCPA)
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen T Chambers, MB ChB, MSc, MD, FRACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Julio A Ramirez, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheila Bond, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 17, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Legionella
         </em>
         bacteria are intracellular pathogens and are important causes of community-acquired and nosocomial pneumonia. Pneumonia caused by
         <em>
          Legionella
         </em>
         bacteria is termed Legionnaires' disease. Legionnaires' disease can be severe, and early administration of appropriate antimicrobial therapy is associated with improved outcomes.
        </p>
        <p>
         <em>
          Legionella
         </em>
         infection can also cause Pontiac fever, a nonspecific febrile illness typically identified during outbreaks. Pontiac fever is typically self-limited and resolves without antimicrobial therapy.
        </p>
        <p>
         The majority of
         <em>
          Legionella
         </em>
         infections are acquired sporadically, but some are associated with outbreaks. Early identification of common environmental sources of infection, such as contaminated water supplies, is key to prevention.
        </p>
        <p>
         The treatment and prevention of
         <em>
          Legionella
         </em>
         infections will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7029.html" rel="external">
          "Microbiology, epidemiology, and pathogenesis of
          <i>
           Legionella
          </i>
          infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7035.html" rel="external">
          "Clinical manifestations and diagnosis of
          <i>
           Legionella
          </i>
          infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1418137469">
         <span class="h1">
          TREATMENT OF LEGIONNAIRES' DISEASE (LEGIONELLA
          <i>
          </i>
          PNEUMONIA)
         </span>
        </p>
        <p class="headingAnchor" id="H1353763555">
         <span class="h2">
          Empiric treatment
         </span>
        </p>
        <p class="headingAnchor" id="H239224760">
         <span class="h3">
          Community-acquired pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Legionella
         </em>
         accounts for approximately 1 to 10 percent of cases of community-acquired pneumonia (CAP) [
         <a href="#rid1">
          1-4
         </a>
         ]. For most patients with CAP, the etiology is not known at the time of diagnosis, and empiric treatment is appropriate.
        </p>
        <p>
         We generally include an antibiotic that targets
         <em>
          Legionella
         </em>
         (eg, a fluoroquinolone or macrolide) when selecting an empiric antibiotic regimen for most patients with CAP. Selection among these agents and the need for treatment with additional antibiotics varies based on pneumonia severity, patient comorbidities, and local epidemiology  (
         <a class="graphic graphic_algorithm graphicRef111829" href="/z/d/graphic/111829.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef112543" href="/z/d/graphic/112543.html" rel="external">
          algorithm 2
         </a>
         ). There is a lack of standardization of in vitro resistance testing and a paucity of comparative clinical trials published, so evidence is incomplete. Consequently, we generally avoid tetracyclines for legionellosis. Destructases have been identified in both
         <em>
          Legionella longbeachae
         </em>
         and
         <em>
          Legionella jordanis
         </em>
         , and the minimum inhibitory concentrations of
         <em>
          Legionella pneumophila
         </em>
         on in vitro testing appear higher than with other agents [
         <a href="#rid5">
          5-9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">
          "Treatment of community-acquired pneumonia in adults in the outpatient setting"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization"
         </a>
         .)
        </p>
        <p>
         Although large meta-analyses have not shown consistent benefit for empiric treatment of atypical pathogens (eg,
         <em>
          Legionella
         </em>
         ,
         <em>
          Mycoplasma
         </em>
         ,
         <em>
         </em>
         and
         <em>
          Chlamydia
         </em>
         species) in all-comers with CAP [
         <a href="#rid10">
          10-12
         </a>
         ], in a subgroup analysis of 43 patients with CAP caused by
         <em>
          L. pneumophila,
         </em>
         clinical failure was reduced when comparing empiric regimens that included coverage for atypical pathogens with regimens that lack such coverage (risk ratio [RR] 0.17, 95% CI 0.05-0.63) [
         <a href="#rid11">
          11
         </a>
         ]. In addition, observational data suggest that delays in appropriate antibiotic therapy are associated with increased mortality in patients with CAP caused by
         <em>
          Legionella
         </em>
         spp [
         <a href="#rid13">
          13,14
         </a>
         ]. Because Legionnaires' disease is indistinguishable from other forms of pneumonia without diagnostic testing, we take an inclusive approach to empiric treatment.
        </p>
        <p>
         Our approach is largely consistent with the Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) guidelines, which recommend including one of these antibiotics in the empiric treatment regimen for most patients with CAP [
         <a href="#rid15">
          15
         </a>
         ]. In contrast, the British Thoracic Society (BTS) and National Institute for Health and Care Excellence (NICE) guidelines reserve use of agents that target atypical pathogens, such as
         <em>
          Legionella,
         </em>
         for patients with moderate to severe CAP or when
         <em>
          Legionella
         </em>
         infection is suspected based on clinical and/or epidemiologic features [
         <a href="#rid16">
          16-19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3895589296">
         <span class="h3">
          Nosocomial pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of Legionnaires' disease are sporadic and community acquired. However, contamination of water supplies in large facilities, such as hospitals and nursing homes, can lead to outbreaks [
         <a href="#rid20">
          20-22
         </a>
         ]. When a
         <em>
          Legionella
         </em>
         outbreak is known or suspected, we include an antibiotic that targets
         <em>
          Legionella
         </em>
         (eg, a fluoroquinolone or macrolide) in empiric antibiotic regimens for the treatment of pneumonia acquired in health care settings.
        </p>
        <p>
         As with CAP, selection among these agents and the need for treatment with additional antibiotics varies based on pneumonia severity, patient comorbidities, and hospital epidemiology  (
         <a class="graphic graphic_algorithm graphicRef109526" href="/z/d/graphic/109526.html" rel="external">
          algorithm 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef109525" href="/z/d/graphic/109525.html" rel="external">
          algorithm 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">
          "Treatment of hospital-acquired and ventilator-associated pneumonia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">
          "Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Empiric therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2498450708">
         <span class="h2">
          Directed treatment
         </span>
        </p>
        <p class="headingAnchor" id="H391231773">
         <span class="h3">
          Antibiotic selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          Levofloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         are the preferred agents for the treatment of Legionnaires' disease because these agents are bactericidal, achieve high intracellular concentrations, penetrate lung tissue, and are active against all
         <em>
          Legionella
         </em>
         species that cause human infection. Alternatives include other fluoroquinolones (eg,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ) and other macrolides (eg,
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , roxithromycin)  (
         <a class="graphic graphic_table graphicRef117791" href="/z/d/graphic/117791.html" rel="external">
          table 1
         </a>
         ). We generally do not use tetracyclines (eg,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ) for empiric treatment because resistance is common among
         <em>
          L. longbeachae.
         </em>
        </p>
        <p>
         For patients with microbiologically confirmed Legionnaires' disease (eg, positive polymerase chain reaction [PCR], urine antigen test, or sputum culture), we generally tailor the initial empiric regimen to a single antibiotic that targets
         <em>
          Legionella
         </em>
         . Coinfection with other pathogens is rare [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with moderate or severe pneumonia (any hospitalized patient or patient with a CRB/CURB-65 score ≥1 (
         <a class="calc calc_professional" href="/z/d/html/16316.html" rel="external">
          calculator 1
         </a>
         ) or Pneumonia Severity Indices [PSI] &gt;II (
         <a class="calc calc_professional" href="/z/d/html/13488.html" rel="external">
          calculator 2
         </a>
         )) caused by any
         <em>
          Legionella
         </em>
         species, we use a fluoroquinolone (eg,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ) or a macrolide (eg,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         ). We generally give these antibiotics intravenously for most hospitalized patients and transition to oral therapy as soon as the patient is clinically improving, hemodynamically stable, and able to tolerate oral therapy. As a general caveat, severity scores should be used as an adjunct to clinical judgement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with mild pneumonia (CRB/CURB-65 scores of 0 or PSI of I to II) caused by
         <em>
          L. pneumophila
         </em>
         , we prefer to use
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         . However, it is not necessary to change therapy to one of these agents for patients who are being treated with other fluoroquinolones, other macrolides, or tetracyclines and are responding to therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with mild pneumonia caused by
         <em>
          L. longbeachae,
         </em>
         we use either a fluoroquinolone or macrolide because
         <em>
          L. longbeachae
         </em>
         is often resistant to tetracyclines [
         <a href="#rid5">
          5-7
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         There are no randomized trials that have directly evaluated the efficacy and side effects of anti-
         <em>
          Legionella
         </em>
         antibiotics. However, cohort studies have not found differences in mortality when comparing
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         with
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         [
         <a href="#rid24">
          24-27
         </a>
         ]. Higher doses of levofloxacin (ie, 750 mg daily) may lead to faster symptom resolution than lower doses (500 mg daily) [
         <a href="#rid28">
          28
         </a>
         ]; we therefore choose higher doses when using this drug. Macrolides other than azithromycin are bacteriostatic against
         <em>
          Legionella
         </em>
         [
         <a href="#rid29">
          29,30
         </a>
         ] and appear to be less effective than either levofloxacin or azithromycin [
         <a href="#rid25">
          25,31,32
         </a>
         ].
        </p>
        <p>
         Combination therapy using both a fluoroquinolone and a macrolide does not appear to improve outcomes [
         <a href="#rid24">
          24,25
         </a>
         ]. Adding
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         (an agent that achieves high intracellular concentrations and can penetrate biofilms) to either fluoroquinolone or macrolide monotherapy does not appear to improve outcomes but may increase adverse events [
         <a href="#rid31">
          31,33
         </a>
         ].
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          Tigecycline
         </a>
         has been reported to be effective salvage therapy for some patients with refractory
         <em>
          L. pneumophila
         </em>
         infections. The activity of tigecycline against
         <em>
          L. longbeachae
         </em>
         is not known but, like its
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         relatives, tigecycline may be inactive against
         <em>
          L. longbeachae
         </em>
         [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3863835583">
         <span class="h3">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal duration of therapy for the treatment of Legionnaires' disease has not been determined and varies with the antibiotic selected, severity of illness, and patient response to therapy  (
         <a class="graphic graphic_table graphicRef117791" href="/z/d/graphic/117791.html" rel="external">
          table 1
         </a>
         ). In general, we treat for a minimum of five days and do not stop therapy until the patient is clinically stable and afebrile for at least 48 hours. Patients with severe pneumonia or chronic comorbidities may be slow to respond to therapy and often require 7 to 10 days of treatment. Patients with complications (eg, lung abscess, empyema, or extrapulmonary infection) and immunosuppressed patients typically need extended courses of therapy [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="local">
          'Immunocompromised patients'
         </a>
         below.)
        </p>
        <p>
         Procalcitonin is increasingly used to help determine antibiotic duration in patients with CAP. However, its utility in patients with Legionnaires' disease is not well established. Procalcitonin levels do rise with Legionnaires' disease but may not rise to the same degree as with pneumonia caused by typical pathogens such as
         <em>
          Streptococcus pneumoniae
         </em>
         [
         <a href="#rid37">
          37-39
         </a>
         ]. Thus, it is unclear whether procalcitonin thresholds used to guide antibiotic therapy in patients with CAP in general can be applied to patients with Legionnaires' disease. (See
         <a class="medical medical_review" href="/z/d/html/114753.html" rel="external">
          "Procalcitonin use in lower respiratory tract infections", section on 'Variability among pathogens'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1849744574">
         <span class="h2">
          Immunocompromised patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transplant recipients and other immunocompromised patients with Legionnaires' disease are at risk for both severe infection and relapse [
         <a href="#rid36">
          36,40-42
         </a>
         ]. Therefore, we select either
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         and treat for a minimum of 14 days, adjusting the total course based on clinical response. Potential drug interactions and adverse effects should be taken into account when selecting between these two antibiotics [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Because of the risk of relapse, we also consider reducing immunosuppression when possible. If prolonged and high levels of immunosuppression are required, a suppressive course of therapy (eg, three to six months) can be given. We make these decisions on case-by-case basis.
        </p>
        <p class="headingAnchor" id="H1495064232">
         <span class="h2">
          Adjunctive treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjunctive glucocorticoid use may be helpful in patients with severe Legionnaires' disease. Because
         <em>
          Legionella
         </em>
         infections induce an intense inflammatory response, glucocorticoid treatment is appealing. However, this intervention is not better studied in Legionnaires' disease than in other types of pneumonia. Indications for use are the same as those for any patient with severe pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Adjunctive glucocorticoids'
         </a>
         .)
        </p>
        <p>
         Extracorporeal membrane oxygenation (ECMO) is a potential option for patients with severe, but potentially reversible, acute respiratory failure. Observational data suggest that survival rates with ECMO use may be as high as 85 percent in patients with Legionnaires' disease [
         <a href="#rid44">
          44-47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview"
         </a>
         .)
        </p>
        <p>
         Surgical drainage or debridement may be needed in patients with empyema who fail medical therapy [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/119384.html" rel="external">
          "Management and prognosis of parapneumonic pleural effusion and empyema in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1011023440">
         <span class="h2">
          Response to treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with Legionnaires' disease respond promptly to treatment, defervescing in approximately two to five days [
         <a href="#rid32">
          32,48
         </a>
         ]. Resolution of radiographic changes often lag behind clinical improvement, though most clear over a period of two months [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         Some patients progress despite therapy. Up to 44 percent of patients require intensive care unit admission, and mortality ranges from approximately 1 to 10 percent [
         <a href="#rid50">
          50-52
         </a>
         ]. Factors associated with poorer outcomes include nosocomial acquisition, delay in appropriate antibiotic therapy, older age, immunosuppression, and the presence of chronic comorbidities [
         <a href="#rid13">
          13,14,53-55
         </a>
         ]. The prognosis for
         <em>
          L. longbeachae
         </em>
         is similar to
         <em>
          L. pneumophila
         </em>
         [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         For patients who are slow to respond to treatment, complications such as lung abscess, empyema, or extrapulmonary infection should be considered. Coinfection with other pathogens is rare but has been reported among patients with nosocomial Legionnaires' disease [
         <a href="#rid57">
          57,58
         </a>
         ]. Other causes of nonresolving pneumonia should also be considered. (See
         <a class="medical medical_review" href="/z/d/html/6992.html" rel="external">
          "Nonresolving pneumonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3161797883">
         <span class="h1">
          TREATMENT OF OTHER
          <i>
           LEGIONELLA
          </i>
          INFECTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2178303294">
         <span class="h2">
          Extrapulmonary disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with extrapulmonary infections (eg, cellulitis, skin abscesses, septic arthritis, myocarditis, or endocarditis) are most often treated with a fluoroquinolone (eg,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ). However, antibiotic selection, duration, and need for other interventions (eg, incision and drainage) varies with the site and severity of infection [
         <a href="#rid59">
          59
         </a>
         ]. Generally, longer courses of therapy are required for patients with extrapulmonary legionellosis than with Legionnaires' disease. Because extrapulmonary infections often occur in immunocompromised patients, reducing immunosuppression (when feasible) may help achieve cure. (See
         <a class="local">
          'Immunocompromised patients'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2667348516">
         <span class="h2">
          Pontiac fever
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pontiac fever is usually short lived and resolves spontaneously after three to five days. Specific therapy is not needed.
        </p>
        <p class="headingAnchor" id="H316162259">
         <span class="h1">
          PREVENTION OF
          <i>
           LEGIONELLA
          </i>
          INFECTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3170271607">
         <span class="h2">
          Patient precautions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with confirmed or suspected
         <em>
          Legionella
         </em>
         infection do not require isolation or contact precautions. Although
         <em>
          Legionella
         </em>
         infections are associated with outbreaks, person-to-person spread is exceedingly rare, with only one possible case reported [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2811195988">
         <span class="h2">
          Outbreak identification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of a single case of
         <em>
          Legionella
         </em>
         infection should prompt suspicion for an outbreak. Although most cases are acquired sporadically, some are linked to a common source such as a contaminated water supply or contaminated soil. Outbreak investigations are typically prompted by the identification of
         <em>
          Legionella
         </em>
         in the microbiology laboratory and further coordinated by hospital epidemiologists and/or local public health authorities. However, clinicians should be prepared to assist in the investigation by obtaining clinical and epidemiologic information from the patient as appropriate.
        </p>
        <p class="headingAnchor" id="H165985962">
         <span class="h2">
          Environmental measures
         </span>
        </p>
        <p class="headingAnchor" id="H3656011941">
         <span class="h3">
          Disinfection of the water supply
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disinfection of water distribution systems and surveillance for
         <em>
          Legionella
         </em>
         contamination are routine practices in water management, particularly in large water distribution systems in developed countries [
         <a href="#rid61">
          61-66
         </a>
         ]. The primary methods for controlling
         <em>
          Legionella
         </em>
         contamination in water distribution systems include copper-silver ionization, hyperchlorination, thermal shock, chlorine dioxide, monochloramine, and point-of-use filters [
         <a href="#rid67">
          67,68
         </a>
         ]. However, cases of legionellosis still occur from treated water systems and may be related to the ability of the
         <em>
          Legionella
         </em>
         spp to survive intracellularly within water-dwelling amoeba [
         <a href="#rid69">
          69
         </a>
         ]. Additionally, not all water supplies are regulated. As an example, drinking water supplies are not routinely monitored for
         <em>
          Legionella
         </em>
         infection, even in developed countries, and continue to serve as a source of infection [
         <a href="#rid21">
          21,70,71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4087552670">
         <span class="h3">
          Preventing soil transmission
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who live in areas where
         <em>
          L. longbeachae
         </em>
         is commonly found in soil (eg, Australia and New Zealand) should be educated on how to prevent inhalation of organism when working with soil or compost [
         <a href="#rid72">
          72
         </a>
         ]. For example, gardeners should be advised to wash their hands after gardening and should avoid touching their face before washing their hands. Those handling compost should be advised to open bags away from the face and to keep compost close to the ground when moving it around. Persons at higher risk for
         <em>
          Legionella
         </em>
         infection (eg, smokers, persons with chronic lung disease, and immunocompromised patients) should be particularly careful.
        </p>
        <p class="headingAnchor" id="H4182900204">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/104226.html" rel="external">
          "Society guideline links: Community-acquired pneumonia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21954908">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale for antibiotic selection
         </strong>
         −
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          Levofloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         are the preferred agents for the treatment of Legionnaires' disease because these agents are bactericidal, achieve high intracellular concentrations, penetrate lung tissue, and are active against all
         <em>
          Legionella
         </em>
         species that cause human infection. (See
         <a class="local">
          'Antibiotic selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Importance of early antibiotic administration
         </strong>
         − Because early administration of appropriate antibiotics has been shown to decrease mortality associated with
         <em>
          Legionella
         </em>
         infection, we generally include one of these agents when selecting an empiric antibiotic regimen for any patient with community-acquired pneumonia. (See
         <a class="local">
          'Empiric treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibiotic selection
         </strong>
         − For patients with confirmed
         <em>
          Legionella
         </em>
         pneumonia, we prefer to use
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         . Alternatives include
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , and roxithromycin  (
         <a class="graphic graphic_table graphicRef117791" href="/z/d/graphic/117791.html" rel="external">
          table 1
         </a>
         ). We generally do not use tetracyclines (eg,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ) because resistance is common among
         <em>
          Legionella longbeachae.
         </em>
         (See
         <a class="local">
          'Directed treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment duration (most patients)
         </strong>
         − In general, we treat patients with Legionnaires' disease for a minimum of 5 days and do not stop therapy until the patient is clinically stable and afebrile for at least 48 hours. Patients with severe pneumonia or chronic comorbidities may be slow to respond to therapy and often require 7 to 10 days of treatment. (See
         <a class="local">
          'Duration of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment duration (immunocompromised)
         </strong>
         − Transplant recipients and other immunocompromised patients are at risk for both severe infection and relapse. Thus, we generally treat for a minimum of 14 days and consider reducing immunosuppression (when feasible) in immunocompromised patients. (See
         <a class="local">
          'Immunocompromised patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response to treatment
         </strong>
         − Most patients defervesce about two to five days after starting therapy, though, in a minority, infection can be fulminant. Up to 44 percent of patients require intensive care unit admission, and the associated mortality is approximately 1 to 10 percent. (See
         <a class="local">
          'Response to treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extrapulmonary diseases
         </strong>
         − Patients with extrapulmonary infections (eg cellulitis, skin abscesses, septic arthritis, or endocarditis) are most often treated with
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         . However, antibiotic selection, duration of therapy, and need for additional interventions (eg, incision and drainage) vary with the site and severity of infection. (See
         <a class="local">
          'Extrapulmonary disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pontiac fever
         </strong>
         − In contrast with other
         <em>
          Legionella
         </em>
         infection, Pontiac fever is typically a self-limited illness that resolves in about two to five days without antibiotic therapy. (See
         <a class="local">
          'Pontiac fever'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Precautions
         </strong>
         − Patients with confirmed or suspected
         <em>
          Legionella
         </em>
         infection do not require isolation or contact precautions. Although
         <em>
          Legionella
         </em>
         infections are associated with outbreaks, person-to-person spread is exceedingly rare. (See
         <a class="local">
          'Patient precautions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preventive measures
         </strong>
         − Key preventive measures include early identification of outbreaks, routine water distribution disinfection, and safe handling of soil and compost. (See
         <a class="local">
          'Prevention of Legionella infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1687562496">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Victor Yu, MD, Nieves Sopena Galindo, MD, and Patricia Priest, MBChB, DPhil, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Abers MS, Bartlett JG. Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus. Clin Infect Dis 2017; 65:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchello C, Dale AP, Thai TN, et al. Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis. Ann Fam Med 2016; 14:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Baum H, Ewig S, Marre R, et al. Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis 2008; 46:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forsberg KJ, Patel S, Wencewicz TA, Dantas G. The Tetracycline Destructases: A Novel Family of Tetracycline-Inactivating Enzymes. Chem Biol 2015; 22:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park J, Gasparrini AJ, Reck MR, et al. Plasticity, dynamics, and inhibition of emerging tetracycline resistance enzymes. Nat Chem Biol 2017; 13:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isenman H, Anderson T, Chambers ST, et al. Antimicrobial susceptibilities of clinical Legionella longbeachae isolates. J Antimicrob Chemother 2018; 73:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph SJ, Cox D, Wolff B, et al. Dynamics of genome change among Legionella species. Sci Rep 2016; 6:33442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portal E, Sands K, Portnojs A, et al. Legionella antimicrobial sensitivity testing: comparison of microbroth dilution with BCYE and LASARUS solid media. J Antimicrob Chemother 2021; 76:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eljaaly K, Alshehri S, Aljabri A, et al. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis 2017; 17:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012; :CD004418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005; 330:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heath CH, Grove DI, Looke DF. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis 1996; 15:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levcovich A, Lazarovitch T, Moran-Gilad J, et al. Complex clinical and microbiological effects on Legionnaires' disease outcone; A retrospective cohort study. BMC Infect Dis 2016; 16:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim WS, Woodhead M, British Thoracic Society. British Thoracic Society adult community acquired pneumonia audit 2009/10. Thorax 2011; 66:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl 3:iii1.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence. Pneumonia in adults: Diagnosis and management. https://www.nice.org.uk/guidance/cg191 (Accessed on December 12, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim WS, Smith DL, Wise MP, et al. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. Thorax 2015; 70:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           David S, Afshar B, Mentasti M, et al. Seeding and Establishment of Legionella pneumophila in Hospitals: Implications for Genomic Investigations of Nosocomial Legionnaires' Disease. Clin Infect Dis 2017; 64:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demirjian A, Lucas CE, Garrison LE, et al. The importance of clinical surveillance in detecting legionnaires' disease outbreaks: a large outbreak in a hospital with a Legionella disinfection system-Pennsylvania, 2011-2012. Clin Infect Dis 2015; 60:1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal S, Abell V, File TM Jr. Nosocomial (Health Care-Associated) Legionnaire's Disease. Infect Dis Clin North Am 2017; 31:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murdoch DR, Podmore RG, Anderson TP, et al. Impact of routine systematic polymerase chain reaction testing on case finding for Legionnaires' disease: a pre-post comparison study. Clin Infect Dis 2013; 57:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cecchini J, Tuffet S, Sonneville R, et al. Antimicrobial strategy for severe community-acquired legionnaires' disease: a multicentre retrospective observational study. J Antimicrob Chemother 2017; 72:1502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Vidal C, Sanchez-Rodriguez I, Simonetti AF, et al. Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis. Clin Microbiol Infect 2017; 23:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jasper AS, Musuuza JS, Tischendorf JS, et al. Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis. Clin Infect Dis 2021; 72:1979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres A, Cillóniz C. Are Macrolides as Effective as Fluoroquinolones in Legionella Pneumonia? Yes, but…. Clin Infect Dis 2021; 72:1990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunbar LM, Khashab MM, Kahn JB, et al. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edelstein PH, Edelstein MA. In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob Agents Chemother 1991; 35:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jonas D, Engels I, Daschner FD, Frank U. The effect of azithromycin on intracellular Legionella pneumophila in the Mono Mac 6 cell line at serum concentrations attainable in vivo. J Antimicrob Chemother 2000; 46:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blázquez Garrido RM, Espinosa Parra FJ, Alemany Francés L, et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mykietiuk A, Carratalà J, Fernández-Sabé N, et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005; 40:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grau S, Antonio JM, Ribes E, et al. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia. Int J Antimicrob Agents 2006; 28:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bopp LH, Baltch AL, Ritz WJ, et al. Activities of tigecycline and comparators against Legionella pneumophila and Legionella micdadei extracellularly and in human monocyte-derived macrophages. Diagn Microbiol Infect Dis 2011; 69:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2003; 47:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pouderoux C, Ginevra C, Descours G, et al. Slowly or Nonresolving Legionnaires' Disease: Case Series and Literature Review. Clin Infect Dis 2020; 70:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haeuptle J, Zaborsky R, Fiumefreddo R, et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellmann-Weiler R, Ausserwinkler M, Kurz K, et al. Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia. J Clin Microbiol 2010; 48:1915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia. Clin Infect Dis 2017; 65:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han JH, Nguyen JC, Harada S, et al. Relapsing Legionella pneumophila cellulitis: a case report and review of the literature. J Infect Chemother 2010; 16:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivagnanam S, Podczervinski S, Butler-Wu SM, et al. Legionnaires' disease in transplant recipients: A 15-year retrospective study in a tertiary referral center. Transpl Infect Dis 2017; 19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayashi M, Kuraishi H, Masubuchi T, et al. A Fatal Case of Relapsing Pneumonia Caused by Legionella pneumophila in a Patient with Rheumatoid Arthritis After Two Injections of Adalimumab. Clin Med Insights Case Rep 2013; 6:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Htwe TH, Khardori NM. Legionnaire's Disease and Immunosuppressive Drugs. Infect Dis Clin North Am 2017; 31:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryner B, Miskulin J, Smith C, et al. Extracorporeal life support for acute respiratory distress syndrome due to severe Legionella pneumonia. Perfusion 2014; 29:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noah MA, Ramachandra G, Hickey MM, et al. Extracorporeal membrane oxygenation and severe acute respiratory distress secondary to Legionella: 10 year experience. ASAIO J 2013; 59:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roncon-Albuquerque R Jr, Vilares-Morgado R, van der Heijden GJ, et al. Outcome and Management of Refractory Respiratory Failure With Timely Extracorporeal Membrane Oxygenation: Single-Center Experience With Legionella Pneumonia. J Intensive Care Med 2019; 34:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naqvi A, Kapoor S, Pradhan M, Dicpinigaitis PV. Outcomes of severe Legionella pneumonia requiring extracorporeal membrane oxygenation (ECMO). J Crit Care 2021; 61:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández JA, López P, Orozco D, Merino J. Clinical study of an outbreak of Legionnaire's disease in Alcoy, Southeastern Spain. Eur J Clin Microbiol Infect Dis 2002; 21:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan MJ, Tan JS, Hamor RH, et al. The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest 2000; 117:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dominguez A, Alvarez J, Sabria M, et al. Factors influencing the case-fatality rate of Legionnaires' disease. Int J Tuberc Lung Dis 2009; 13:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jespersen S, Søgaard OS, Schønheyder HC, et al. Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: a Danish historical cohort study. BMC Infect Dis 2010; 10:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sopena N, Force L, Pedro-Botet ML, et al. Sporadic and epidemic community legionellosis: two faces of the same illness. Eur Respir J 2007; 29:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gacouin A, Le Tulzo Y, Lavoue S, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med 2002; 28:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch Intern Med 1994; 154:2417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chidiac C, Che D, Pires-Cronenberger S, et al. Factors associated with hospital mortality in community-acquired legionellosis in France. Eur Respir J 2012; 39:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isenman HL, Chambers ST, Pithie AD, et al. Legionnaires' disease caused by Legionella longbeachae: Clinical features and outcomes of 107 cases from an endemic area. Respirology 2016; 21:1292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrie TJ, Haldane D, Bezanson G. Nosocomial Legionnaires' disease: Clinical and radiographic patterns. Can J Infect Dis 1992; 3:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer RD, Edelstein PH, Kirby BD, et al. Legionnaires' disease: unusual clinical and laboratory features. Ann Intern Med 1980; 93:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowry PW, Tompkins LS. Nosocomial legionellosis: a review of pulmonary and extrapulmonary syndromes. Am J Infect Control 1993; 21:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correia AM, Ferreira JS, Borges V, et al. Probable Person-to-Person Transmission of Legionnaires' Disease. N Engl J Med 2016; 374:497.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention (CDC). Legionella (Legionnaires' Disease and Pontiac Fever): Water System Maintenance. https://www.cdc.gov/legionella/water-system-maintenance.html (Accessed on March 01, 2018).
         </li>
         <li class="breakAll">
          Health and Safety Executive: Legionella and Legionnaire's disease http://www.hse.gov.uk/legionnaires/index.htm (Accessed on March 01, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           McClung RP, Roth DM, Vigar M, et al. Waterborne Disease Outbreaks Associated With Environmental and Undetermined Exposures to Water - United States, 2013-2014. MMWR Morb Mortal Wkly Rep 2017; 66:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehret KM, Chamberlain AT, Berkelman RL, Fridkin SK. Preventing hospital-acquired Legionnaires' disease: A snapshot of clinical practices and water management approaches in US acute-care hospitals. Infect Control Hosp Epidemiol 2018; 39:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sciuto EL, Laganà P, Filice S, et al. Environmental Management of Legionella in Domestic Water Systems: Consolidated and Innovative Approaches for Disinfection Methods and Risk Assessment. Microorganisms 2021; 9.
          </a>
         </li>
         <li class="breakAll">
          Management of Legionella in Water Systems, National Academies Press (US).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchesi I, Marchegiano P, Bargellini A, et al. Effectiveness of different methods to control legionella in the water supply: ten-year experience in an Italian university hospital. J Hosp Infect 2011; 77:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quero S, Párraga-Niño N, Garcia-Núñez M, et al. The impact of pipeline changes and temperature increase in a hospital historically colonised with Legionella. Sci Rep 2021; 11:1916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cervero-Aragó S, Rodríguez-Martínez S, Puertas-Bennasar A, Araujo RM. Effect of Common Drinking Water Disinfectants, Chlorine and Heat, on Free Legionella and Amoebae-Associated Legionella. PLoS One 2015; 10:e0134726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin YE, Stout JE, Yu VL. Controlling Legionella in hospital drinking water: an evidence-based review of disinfection methods. Infect Control Hosp Epidemiol 2011; 32:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benedict KM, Reses H, Vigar M, et al. Surveillance for Waterborne Disease Outbreaks Associated with Drinking Water - United States, 2013-2014. MMWR Morb Mortal Wkly Rep 2017; 66:1216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenagy E, Priest PC, Cameron CM, et al. Risk Factors for Legionella longbeachae Legionnaires' Disease, New Zealand. Emerg Infect Dis 2017; 23:1148.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7025 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29028977" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28376442" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18419436" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26172429" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26097034" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The Tetracycline Destructases: A Novel Family of Tetracycline-Inactivating Enzymes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28481346" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Plasticity, dynamics, and inhibition of emerging tetracycline resistance enzymes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29272402" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Antimicrobial susceptibilities of clinical Legionella longbeachae isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27633769" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Dynamics of genome change among Legionella species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33367732" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Legionella antimicrobial sensitivity testing: comparison of microbroth dilution with BCYE and LASARUS solid media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28576117" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972070" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15684024" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8781878" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Delay in appropriate therapy of Legionella pneumonia associated with increased mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26864322" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Complex clinical and microbiological effects on Legionnaires' disease outcone; A retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21502103" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : British Thoracic Society adult community acquired pneumonia audit 2009/10.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19783532" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : BTS guidelines for the management of community acquired pneumonia in adults: update 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19783532" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : BTS guidelines for the management of community acquired pneumonia in adults: update 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25977290" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28203790" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Seeding and Establishment of Legionella pneumophila in Hospitals: Implications for Genomic Investigations of Nosocomial Legionnaires' Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25722201" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The importance of clinical surveillance in detecting legionnaires' disease outbreaks: a large outbreak in a hospital with a Legionella disinfection system-Pennsylvania, 2011-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27979683" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Nosocomial (Health Care-Associated) Legionnaire's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23899682" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Impact of routine systematic polymerase chain reaction testing on case finding for Legionnaires' disease: a pre-post comparison study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28204479" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Antimicrobial strategy for severe community-acquired legionnaires' disease: a multicentre retrospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28267637" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32296816" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32296825" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Are Macrolides as Effective as Fluoroquinolones in Legionella Pneumonia? Yes, but….
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15119993" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1849708" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : In vitro activity of azithromycin against clinical isolates of Legionella species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10980164" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The effect of azithromycin on intracellular Legionella pneumophila in the Mono Mac 6 cell line at serum concentrations attainable in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15736011" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15736010" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16870401" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21146719" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Activities of tigecycline and comparators against Legionella pneumophila and Legionella micdadei extracellularly and in human monocyte-derived macrophages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12543655" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31242293" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Slowly or Nonresolving Legionnaires' Disease: Case Series and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18677519" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Prognostic value of procalcitonin in Legionella pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20220163" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28407054" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20526646" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Relapsing Legionella pneumophila cellulitis: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28696077" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Legionnaires' disease in transplant recipients: A 15-year retrospective study in a tertiary referral center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23843716" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A Fatal Case of Relapsing Pneumonia Caused by Legionella pneumophila in a Patient with Rheumatoid Arthritis After Two Injections of Adalimumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27979686" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Legionnaire's Disease and Immunosuppressive Drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23863490" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Extracorporeal life support for acute respiratory distress syndrome due to severe Legionella pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23644625" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Extracorporeal membrane oxygenation and severe acute respiratory distress secondary to Legionella: 10 year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28330410" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Outcome and Management of Refractory Respiratory Failure With Timely Extracorporeal Membrane Oxygenation: Single-Center Experience With Legionella Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33157304" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Outcomes of severe Legionella pneumonia requiring extracorporeal membrane oxygenation (ECMO).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12415472" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Clinical study of an outbreak of Legionnaire's disease in Alcoy, Southeastern Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10669681" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19275805" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Factors influencing the case-fatality rate of Legionnaires' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20492639" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: a Danish historical cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17005576" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Sporadic and epidemic community legionellosis: two faces of the same illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12107671" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7979837" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22005914" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Factors associated with hospital mortality in community-acquired legionellosis in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27199169" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Legionnaires' disease caused by Legionella longbeachae: Clinical features and outcomes of 107 cases from an endemic area.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22416200" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Nosocomial Legionnaires' disease: Clinical and radiographic patterns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6996551" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Legionnaires' disease: unusual clinical and laboratory features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8442518" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Nosocomial legionellosis: a review of pulmonary and extrapulmonary syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26840151" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Probable Person-to-Person Transmission of Legionnaires' Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26840151" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Probable Person-to-Person Transmission of Legionnaires' Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26840151" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Probable Person-to-Person Transmission of Legionnaires' Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29120997" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Waterborne Disease Outbreaks Associated With Environmental and Undetermined Exposures to Water - United States, 2013-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30293535" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Preventing hospital-acquired Legionnaires' disease: A snapshot of clinical practices and water management approaches in US acute-care hospitals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33799845" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Environmental Management of Legionella in Domestic Water Systems: Consolidated and Innovative Approaches for Disinfection Methods and Risk Assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33799845" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Environmental Management of Legionella in Domestic Water Systems: Consolidated and Innovative Approaches for Disinfection Methods and Risk Assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131100" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effectiveness of different methods to control legionella in the water supply: ten-year experience in an Italian university hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33479467" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The impact of pipeline changes and temperature increase in a hospital historically colonised with Legionella.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26241039" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Effect of Common Drinking Water Disinfectants, Chlorine and Heat, on Free Legionella and Amoebae-Associated Legionella.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21460472" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Controlling Legionella in hospital drinking water: an evidence-based review of disinfection methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29121003" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Surveillance for Waterborne Disease Outbreaks Associated with Drinking Water - United States, 2013-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28628460" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Risk Factors for Legionella longbeachae Legionnaires' Disease, New Zealand.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
